Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Apr 12;17(1):258.
doi: 10.1186/s12885-017-3236-2.

Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol

Charlotte M C Oude Ophuis  1 , Lisa B Koppert  2 , Cécile de Monyé  3 , Carolien H M van Deurzen  4 , Senada Koljenović  4 , Alexander C J van Akkooi  5 , Cornelis Verhoef  2 , Dirk J Grünhagen  2
Affiliations
Multicenter Study

Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol

Charlotte M C Oude Ophuis et al. BMC Cancer. .

Erratum in

Abstract

Background: Sentinel node (SN) biopsy (SNB) detects clinically occult metastases of breast cancer and melanoma in 20-30%. Wound infections, seroma and lymph edema occur in up to 10%. Targeted ultrasound (US) of the SN, (with fine needle aspiration cytology (FNAC) if appropriate) has been investigated as a minimally invasive alternative, but reported sensitivity rates are too low to replace SNB. Our hypothesis is that the use of a handheld gamma probe concomitant with US may improve sensitivity. Our aim is to provide an overview of the current literature on preoperative nodal staging of clinical N0 melanoma patients, report on a pilot, and present a study protocol for a minimally invasive alternative to the SNB: Gamma probe and Ultrasound guided Fine needle aspiration cytology of the sentinel node (GULF trial).

Methods: The GULF trial is a multicenter open single arm observational trial. Newly diagnosed cT1b-4N0M0 cutaneous melanoma or cT1-3N0M0 breast cancer patients, aged >18 years, presenting for SNB are eligible. 120 patients will be included for preoperative targeted gamma probe guided US and FNAC of the SN. Afterwards all patients proceed to surgical SNB. Primary endpoint is the sensitivity of FNAC. Secondary endpoints include SN identification rate and the histopathological compatibility of Core Needle Biopsy and FNAC vs. SNB. Secondary endpoints were investigated in a pilot with 10 FNACs and marker placements, and 10 FNACs combined with Core Needle Biopsy.

Results: A pilot in 20 patients showed that SN identification rate was 90%, supporting the feasibility of this technique.

Discussion: There is broad experience with US (in combination with FNAC) prior to SNB, but sensitivity and specificity are too low to completely abandon SNB. Promising alternative techniques potentially will replace SNB in the future but more evidence is needed in the form of prospective studies. Accurate identification of the SN for US-FNAC has been proven feasible in our pilot. When adequate sensitivity can be reached, US-FNAC provides a minimally invasive alternative for the surgical SNB procedure.

Trial registration: The GULF trial is registered in the Netherlands Trial Registry (NTR), ID: NRT5193 . May 1st 2015.

Keywords: Breast Neoplasms; Fine-needle biopsy; Melanoma; Minimally invasive surgical procedures; Sentinel lymph node biopsy; Ultrasonography.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study Flowchart GULF Trial
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol Jul 2003; 10(6):676-680. - PubMed
    1. Biver-Dalle C, Puzenat E, Puyraveau M, et al. Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009) BMC Dermatol. 2012;12:21. doi: 10.1186/1471-5945-12-21. - DOI - PMC - PubMed
    1. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol Jul 2003; 200(3):314-319. - PubMed
    1. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging Oct 2009; 36(10):1713-1742. - PubMed
    1. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer. Jun 28 2016;63:201-217. - PubMed